SUPN
Supernus Pharmaceuticals Inc
42.40$
+0.5%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | +3.6% | -41.2% | +14.3% | +74.9% | +18.1% | +23.9% | +37.3% | +64.0% | +37.1% | +130.4% | +18.7% | +29.6% | +12.3% | +0.8% | -25.0% | +7.1% | +6.2% | |
| – | – | +4.9% | -45.4% | +24.1% | +85.7% | +5.9% | +12.1% | -2.7% | +42.9% | +50.9% | +116.0% | -4.2% | +33.4% | -4.6% | +22.0% | -32.8% | +39.1% | -6.1% | |
| – | – | -40.6% | -24.4% | +104.5% | +82.3% | -7.1% | -9.6% | -16.3% | +44.9% | +11.3% | +91.7% | -5.7% | +59.1% | -29.5% | -54.2% | -19.4% | -7.6% | +85.3% | |
| – | – | +10.2% | -50.8% | +48.4% | +82.3% | -7.1% | -9.6% | -16.3% | +44.9% | +55.4% | +154.2% | -2.5% | +21.7% | -19.6% | +35.8% | -44.8% | +78.0% | -32.0% | |
| – | – | +64.4% | -95.8% | -19.0% | +427.3% | +648.7% | +241.7% | +50.0% | +60.3% | +57.9% | +56.9% | -15.1% | +61.3% | +5.7% | +11.1% | -12.9% | -1.4% | +32.2% | |
| – | – | -64.2% | +187.8% | -94.2% | +196.1% | +520.8% | +87.9% | -6.4% | +33.5% | -3.0% | +57.4% | +3.8% | +81.5% | +77.9% | +6.5% | -15.4% | -29.9% | +51.7% | |
| – | – | – | – | – | +8.5% | +79.7% | -4.2% | +58.3% | +12.1% | +18.0% | -20.1% | +316.8% | +121.6% | +38.3% | -15.8% | – | – | – | |
| – | – | – | – | – | – | +69.5% | +369.3% | -82.0% | +1,589.5% | +118.4% | -12.9% | -20.8% | +213.7% | +50.8% | -0.4% | +0.0% | +0.0% | +6.7% | |
| – | – | -14.3% | -16.7% | -20.1% | -25.1% | +69.5% | +369.3% | -82.0% | +1,589.5% | +118.4% | -12.9% | -20.8% | +1,366.8% | +115.4% | -10.5% | -14.6% | -13.0% | +9.1% | |
| – | – | +2.6% | +6.1% | -51.5% | -17.8% | +112.9% | -14.7% | +5.6% | +68.7% | +33.2% | +234.3% | +7.6% | +34.4% | +15.0% | -6.5% | -56.4% | -6.7% | +17.6% | |
| – | – | +21.3% | +51.6% | +23.4% | +22.4% | +14.9% | +4.1% | +104.0% | +43.9% | +52.3% | +31.2% | -0.5% | +52.6% | +28.7% | +118.1% | -57.8% | +0.8% | +15.7% | |
| – | – | – | – | – | +44.3% | +56.8% | +41.6% | -98.1% | +13,859.2% | -93.8% | -49.0% | +29.4% | +33.1% | +72.3% | +6,210.9% | -98.0% | -17.3% | +54.0% | |
| – | – | +39.8% | +80.4% | -10.5% | -72.2% | +552.7% | -89.8% | +131.6% | +86.7% | -15.0% | -53.3% | +217.4% | -39.4% | +51.8% | +13.0% | -81.4% | +133.6% | -41.6% | |
| – | – | – | – | – | -51.2% | +210.2% | -21.6% | -73.7% | -41.2% | -100.0% | – | +4.8% | +4.8% | +4.8% | – | – | – | – | |
| – | – | – | – | – | +509.7% | -41.9% | +113.2% | +66.6% | +61.3% | +39.5% | +69.4% | +31.4% | +25.1% | +9.5% | +8.6% | +4.0% | +12.4% | +2.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | +130.7% | +63.6% | +16.4% | +26.7% | +0.3% | +15.3% | -6.9% | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +25.9% | +82.6% | +58.8% | +1.1% | +1.1% | +3.1% | +1.5% | -0.5% | -0.2% | +1.2% | +13.5% | -10.0% | +0.8% | +0.9% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.